Alliance was founded in 1996 by John Dawson, who developed the company over more than twenty years into a successful international business. Alliance commenced trading in 1998, when the company entered into a fostering arrangement with Novartis, under which Alliance took over the marketing and distribution of 16 of Novartis’ speciality prescription brands. Since then the company has grown to owning or licensing the rights to over 90 products.
In May 2018 John stepped down as CEO and handed the baton over to Peter Butterfield, previously deputy CEO. Peter joined Alliance in 2010, and he will continue the development, growth and success of Alliance in the future. John remains on the board as a non-executive director.
The business has grown consistently over the years, through a combination of targeted acquisitions and organic growth, floating on the Alternative Investment Market (AIM) of the London Stock Exchange in 2003.
Recent years have seen a broadening in the scope of Alliance’s product portfolio. In addition to the established niche prescription products which formed the original focus of the company’s activities (and which still constitute the bulk of our business), Alliance’s portfolio now includes a number of medical devices and consumer products, covering a wide range of therapy areas.
Having completed a total of 34 acquisitions to date, together with a number of in-licensing deals, Alliance now owns or licenses the rights to over 90 pharmaceutical and related products. In addition to its UK operations, the company is growing its International footprint and now has a direct presence in France, Germany, the Republic of Ireland and China, with a group turnover of over £100 million.
In recent years the business has expanded its UK head office in Chippenham, Wiltshire, and is one of the main employers in the area.